Viatcheslav R. Akmaev
Viatcheslav R. Akmaev has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Allison Klotz
BPGbio Inc., Waltham, Massachusetts
27 shared publications - Andrew Hendifar
Cedars-Sinai Medical Center, Los Angeles, CA 90211, USA
27 shared publications - Arianne Lyng
BPGbio Inc., Waltham, Massachusetts
27 shared publications - Can Bruce
BPGbio Inc., Waltham, Massachusetts
27 shared publications - David Lucius
BPGbio Inc., Waltham, Massachusetts
27 shared publications - David S. Hong
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
27 shared publications
Latest Publications
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Adverse events of bleeding reported in study subjects. In total, 17 events were reported in 16 patients, including three patients in Arm 1 who received BPM31510IV monotherapy (96-h infusion, n=1; 144-h infusion, n=2) and 13 in Arm 2 who received BPM31510IV in combination with chemotherapy (96-h infusion, n=7; 144-h infusion, n=6).
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Adverse events of bleeding reported in study subjects. In total, 17 events were reported in 16 patients, including three patients in Arm 1 who received BPM31510IV monotherapy (96-h infusion, n=1; 144-h infusion, n=2) and 13 in Arm 2 who received BPM31510IV in combination with chemotherapy (96-h infusion, n=7; 144-h infusion, n=6).
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Grade ≥3 TEAEs reported in at least two cohorts or in >10% of patients in any cohort (bold).
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Grade ≥3 TEAEs reported in at least two cohorts or in >10% of patients in any cohort (bold).
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Demographic information and baseline characteristics for patients enrolled in this phase Ia/Ib study of BPM31510IV.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Demographic information and baseline characteristics for patients enrolled in this phase Ia/Ib study of BPM31510IV.
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Results from exploratory studies. A, Representative 18FDG PET/CT scans. A 53-year-old male with gastric adenocarcinoma with liver and lymph node metastases who received BPM31510IV monotherapy at 66 mg/kg. At the end of two cycles of BPM31510IV, there was a 40% decrease in SUV measures, complete resolution of activity in cervical and lymph node metastases, and decreased activity in the liver (yellow arrows). B, Waterfall plot showing best change in sum SUVmax for all patients with PET/CT results. For patients who crossed over from arm 1 to arm 2, PET/CT scan data after crossover were omitted from the analysis. C, Metabolomics analysis identifies metabolic activity involving fatty acylcarnitines associated with BPM31510IV treatment: enrichment for chemical subclasses among plasma metabolites shows a positive association with plasma CoQ10 levels. Chemical subclasses (y-axis) are shown in terms of their significance (x-axis and dot color) and enrichment ratio relative to the reference metabolome (dot size).
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Results from exploratory studies. A, Representative 18FDG PET/CT scans. A 53-year-old male with gastric adenocarcinoma with liver and lymph node metastases who received BPM31510IV monotherapy at 66 mg/kg. At the end of two cycles of BPM31510IV, there was a 40% decrease in SUV measures, complete resolution of activity in cervical and lymph node metastases, and decreased activity in the liver (yellow arrows). B, Waterfall plot showing best change in sum SUVmax for all patients with PET/CT results. For patients who crossed over from arm 1 to arm 2, PET/CT scan data after crossover were omitted from the analysis. C, Metabolomics analysis identifies metabolic activity involving fatty acylcarnitines associated with BPM31510IV treatment: enrichment for chemical subclasses among plasma metabolites shows a positive association with plasma CoQ10 levels. Chemical subclasses (y-axis) are shown in terms of their significance (x-axis and dot color) and enrichment ratio relative to the reference metabolome (dot size).
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Representativeness of study participants. Numbers of advanced/Stage IV patients with each cancer type/subtype are also shown.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Representativeness of study participants. Numbers of advanced/Stage IV patients with each cancer type/subtype are also shown.
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Waterfall plot showing different combinations of chemotherapy for ARM2 and different doses of BPM31510IV.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Waterfall plot showing different combinations of chemotherapy for ARM2 and different doses of BPM31510IV.
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Treatment-emergent adverse events (TEAEs; all grades) that occurred in ≥10% of patients in any group treated with BPM31510IV in Arms 1 and 2 stratified by cohort.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Treatment-emergent adverse events (TEAEs; all grades) that occurred in ≥10% of patients in any group treated with BPM31510IV in Arms 1 and 2 stratified by cohort.
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Treatment-emergent adverse events (TEAEs; all grades) that occurred in ≥10% of patients in any group treated with BPM31510IV in Arms 1 and 2 stratified by cohort and chemotherapy received.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Treatment-emergent adverse events (TEAEs; all grades) that occurred in ≥10% of patients in any group treated with BPM31510IV in Arms 1 and 2 stratified by cohort and chemotherapy received.
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Waterfall plots showing best response to BPM31510IV patients who had at least one tumor imaging assessment at or following Cycle 2, by cohort. A., Arm 1. B, Arm 2.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Waterfall plots showing best response to BPM31510IV patients who had at least one tumor imaging assessment at or following Cycle 2, by cohort. A., Arm 1. B, Arm 2.
- Open Access
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Metabolites detected in plasma or urine that correlate with systemic protein changes. Further information on the column names is provided in the Patients and Methods and the legend for Table S13.
- 24 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients
Metabolites detected in plasma or urine that correlate with systemic protein changes. Further information on the column names is provided in the Patients and Methods and the legend for Table S13.